# Step 165 - First-Tier Triad Commercial Demonstration Release Scope Review

**Step 165 is a governed commercial-demonstration release review only. It does not authorize or implement Step 166.**

Step 164 was verified as PASS with three equal first-tier tracks, twelve synthetic scenarios, three SHA-256-sealed assurance passports, three RAMAT display feeds, three reconstruction exports, a read-only localhost API, rejected write methods, verified recovery, and no regulated execution.

## Locked doctrine

- Platform B v1 remains ARCHITECTURE LOCKED.
- Thread D v1 remains ARCHITECTURE LOCKED.
- Commercial demonstration orchestration belongs only to Platform B1 / MVP2.
- Thread D2 and RAMAT Vision remain DISPLAY / WITNESS ONLY.
- Qualified humans and authorized organizational roles retain binding authority.
- Official records and execution remain in governed source systems.
- IRLT, compounding pharmacy, and DSCSA remain equal first-tier tracks.
- No production integration, write-back, PHI, physical execution, or real wearable integration is authorized.

## Commercial demonstration releases

| Track | Audience | Passport output | Release status |
|---|---|---|---|
| RELEASE-COMPOUNDING - Compounding Pharmacy Commercial Demonstration Release | Compounding pharmacies; pharmacists; Quality teams; healthcare organizations; inspectors; commercialization partners; investors | Compounding Preparation and Pharmacist Assurance Passport | PROPOSED STEP 166 DEMONSTRATION RELEASE - NOT IMPLEMENTED |
| RELEASE-DSCSA - DSCSA Commercial Demonstration Release | Manufacturers; wholesalers; dispensers; trading partners; supply-chain compliance teams; regulators; commercialization partners; investors | DSCSA Transaction, Trading-Partner, and Custody Assurance Passport | PROPOSED STEP 166 DEMONSTRATION RELEASE - NOT IMPLEMENTED |
| RELEASE-IRLT - IRLT Commercial Demonstration Release | Radiopharmaceutical manufacturers; Quality Units; clinical sites; logistics partners; regulators; investors; research collaborators | IRLT Assurance and Inspection Passport | PROPOSED STEP 166 DEMONSTRATION RELEASE - NOT IMPLEMENTED |

## Commercial track details

### RELEASE-COMPOUNDING - Compounding Pharmacy Commercial Demonstration Release

- Strategic position: Equal first-tier commercialization and demonstration priority
- Primary audience: Compounding pharmacies; pharmacists; Quality teams; healthcare organizations; inspectors; commercialization partners; investors
- Demonstration story: A synthetic patient-specific preparation moves from mock order and formula through ingredient genealogy, calculation, preparation, labeling, pharmacist review, beyond-use timing, and dispensing readiness.
- Baseline proof: Verified order, formula, ingredients, calculations, label, timing, evidence, and pharmacist authority produce ACTION ADMISSIBLE.
- Failure proof: Evidence tampering or label mismatch produces REHASH_MISMATCH or DEPENDENCY UNSATISFIED, NO-BIND STATE ACTIVE, and ACTION HELD.
- Recovery proof: Verified restoration and corrected label state return the synthetic preparation to REHASH_VERIFIED and ACTION ADMISSIBLE.
- Passport output: Compounding Preparation and Pharmacist Assurance Passport
- Console view: Order identity; formula version; ingredient genealogy; calculations; label agreement; beyond-use timing; pharmacist authority; No-Bind; admissibility; reconstruction
- Human authority: Authorized prescriber context, qualified compounding personnel, authorized pharmacist, and accountable pharmacy management
- Source-system boundary: Mock pharmacy, formulation, inventory, equipment, environmental, label, and dispensing systems remain authoritative.
- Authorization state: **NOT AUTHORIZED**

### RELEASE-DSCSA - DSCSA Commercial Demonstration Release

- Strategic position: Equal first-tier commercialization and demonstration priority
- Primary audience: Manufacturers; wholesalers; dispensers; trading partners; supply-chain compliance teams; regulators; commercialization partners; investors
- Demonstration story: A synthetic serialized product moves from manufacturer through aggregation, EPCIS events, transaction evidence, trading-partner authority, custody transfer, verification, suspect-product review, and disposition readiness.
- Baseline proof: Verified serial, lot, aggregation, EPCIS sequence, partner authority, transaction evidence, and suspect-product clearance produce ACTION ADMISSIBLE.
- Failure proof: Evidence tampering or broken EPCIS sequence produces REHASH_MISMATCH or DEPENDENCY UNSATISFIED, NO-BIND STATE ACTIVE, and ACTION HELD.
- Recovery proof: Verified restoration and corrected EPCIS sequence return the synthetic product to REHASH_VERIFIED and ACTION ADMISSIBLE.
- Passport output: DSCSA Transaction, Trading-Partner, and Custody Assurance Passport
- Console view: Product identity; aggregation; EPCIS chronology; transaction evidence; trading-partner authority; suspect-product state; No-Bind; admissibility; reconstruction
- Human authority: Authorized manufacturer, trading-partner, supply-chain, compliance, Quality, investigation, and disposition roles
- Source-system boundary: Mock serialization, EPCIS, ERP, warehouse, trading-partner, verification, and investigation systems remain authoritative.
- Authorization state: **NOT AUTHORIZED**

### RELEASE-IRLT - IRLT Commercial Demonstration Release

- Strategic position: Equal first-tier commercialization and demonstration priority
- Primary audience: Radiopharmaceutical manufacturers; Quality Units; clinical sites; logistics partners; regulators; investors; research collaborators
- Demonstration story: A synthetic AURORA-17 batch moves from QC release through custody, transport, receiving-site readiness, decay-window control, and administration readiness.
- Baseline proof: Verified evidence, identity, dependencies, authority, timing, and custody produce ACTION ADMISSIBLE while official execution remains external.
- Failure proof: Evidence tampering or custody discontinuity produces REHASH_MISMATCH or DEPENDENCY UNSATISFIED, NO-BIND STATE ACTIVE, and ACTION HELD.
- Recovery proof: Verified restoration and corrected custody state return the synthetic case to REHASH_VERIFIED and ACTION ADMISSIBLE.
- Passport output: IRLT Assurance and Inspection Passport
- Console view: Batch identity; evidence integrity; custody chain; decay timing; authority; No-Bind; admissibility; RAMAT display state; reconstruction timeline
- Human authority: Quality Unit, authorized batch releaser, radiation-safety role, logistics custodian, receiving authority, and qualified clinical personnel
- Source-system boundary: Mock MES, LIMS, eQMS, ERP, custody, logistics, and clinical systems remain authoritative.
- Authorization state: **NOT AUTHORIZED**

## Demonstration bundle components

| ID | Component | Purpose |
|---|---|---|
| DEMO-165-01 | Read-Only Commercial Demonstration Console | Display track selection, scenario state, evidence integrity, dependencies, authority, timing, No-Bind, and admissibility without executing actions. |
| DEMO-165-02 | Inspection Passport Viewer | Present sealed identity, provenance, evidence, dependency, authority, timing, decision, and source-of-truth information. |
| DEMO-165-03 | Controlled Scenario Launcher | Launch only prebuilt baseline, tamper, domain-failure, and recovery demonstrations. |
| DEMO-165-04 | RAMAT Vision Preview Panel | Display the same expiring DISPLAY / WITNESS ONLY state intended for wearable presentation. |
| DEMO-165-05 | Evidence Integrity and Rehash Panel | Show sealed hash, current hash, rehash state, evidence sufficiency, and tamper response. |
| DEMO-165-06 | Workflow Dependency Lens | Show satisfied, unsatisfied, stale, missing, and recovered workflow dependencies. |
| DEMO-165-07 | Authority and No-Bind Panel | Show authority presence, validity, scope, timing, human accountability, hold state, and escalation requirement. |
| DEMO-165-08 | Governance Reconstruction Timeline | Present evidence seal, rehash, dependency, authority, No-Bind, admissibility, recovery, and source references. |
| DEMO-165-09 | Demonstration Evidence Export | Export local synthetic JSON, CSV, Markdown, passport, seal, display, reconstruction, and audit artifacts. |

## Release gates

| Gate | Requirement | Status |
|---|---|---|
| GATE-165-01 - Explicit Step 166 Authorization | An accountable human must explicitly authorize Step 166 after reviewing Step 165. | REQUIRED |
| GATE-165-02 - Equal First-Tier Track Preservation | IRLT, compounding pharmacy, and DSCSA remain equal first-tier tracks. | REQUIRED |
| GATE-165-03 - Platform B v1 Architecture Lock | Platform B v1 remains limited to its six frozen MVP capabilities. | LOCKED |
| GATE-165-04 - Thread D v1 Architecture Lock | Thread D v1 remains unchanged. | LOCKED |
| GATE-165-05 - Platform B1 Ownership Boundary | Commercial demonstration orchestration remains inside Platform B1 / MVP2. | REQUIRED |
| GATE-165-06 - RAMAT Display-Only Boundary | Thread D2 and RAMAT Vision remain DISPLAY / WITNESS ONLY. | REQUIRED |
| GATE-165-07 - Read-Only API and Console Boundary | The console and API may read synthetic state but may not perform write-back or regulated execution. | REQUIRED |
| GATE-165-08 - Human Binding Authority | Qualified humans and authorized organizational roles retain binding authority. | REQUIRED |
| GATE-165-09 - Official Source-System Authority | Official records and execution remain in governed source systems. | REQUIRED |
| GATE-165-10 - Synthetic Data Boundary | Only synthetic records, mock identities, and non-production services may be used. | REQUIRED |
| GATE-165-11 - Fail-Closed No-Bind Requirement | Missing, stale, conflicted, invalid, or compromised conditions must create or preserve ACTION HELD. | REQUIRED |
| GATE-165-12 - Evidence Integrity and Recovery Requirement | SHA-256 sealing, rehashing, tamper detection, recovery, tests, and artifact integrity remain mandatory. | REQUIRED |

## Proposed Step 166 scope

- Proposed title: First-Tier Triad Commercial Demonstration Console and Inspection Passport Bundle
- Purpose: Implement a local synthetic read-only demonstration console over the verified Step 164 API for IRLT, compounding pharmacy, and DSCSA. The console will display baseline, tamper, domain-failure, recovery, passport, RAMAT, reconstruction, and audit evidence.
- Security boundary: Localhost only; synthetic data only; GET-only API; no secrets in browser; no production connection; no source-system write-back.
- Authorization state: **NOT AUTHORIZED**
- Authorization reason: Step 166 requires a new explicit accountable-human authorization after Step 165 review.

### Required demonstration states

- BASELINE - ACTION ADMISSIBLE
- EVIDENCE TAMPER - REHASH MISMATCH
- DOMAIN FAILURE - DEPENDENCY UNSATISFIED
- NO-BIND STATE ACTIVE
- ACTION HELD
- VERIFIED RECOVERY
- SOURCE-SYSTEM EXECUTION REQUIRED
- DISPLAY / WITNESS ONLY

### Explicit exclusions

- No Platform B v1 modification
- No Thread D v1 modification
- No production source-system connection
- No production write-back
- No PHI
- No company production data
- No approval or release action
- No dispensing or administration
- No real shipment or product transfer
- No physical wearable integration
- No Azure production deployment
- No regulatory-validation claim

## Step 166 authorization gate

Step 166 must not begin until an accountable human explicitly authorizes the local synthetic read-only First-Tier Triad Commercial Demonstration Console and Inspection Passport Bundle.

**STEP 165 FIRST-TIER TRIAD COMMERCIAL DEMONSTRATION RELEASE SCOPE REVIEW COMPLETE**

**STEP 166: AWAITING EXPLICIT HUMAN AUTHORIZATION**
